Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: mAbs: Overview • Evolution of mAb therapeutics • Conjugated cancer therapies using mAbs PART 06: Timeline of mAbs for cancer PART 07: Pipeline portfolio • List of Phase III pipeline molecules • List of Phase II pipeline molecules • List of Phase I pipeline molecules PART 08: Market landscape • Market overview • Five forces analysis PART 09: Market segmentation by type of mAbs • Naked mAbs • Conjugated mAbs PART 10: Market segmentation by MOA • Immune system suppressors • Kill or inhibit malignant cells • Angiogenesis inhibitors • Radiation therapy to cancer cells • Delivering chemotherapy to cancer cells PART 11: Geographical segmentation • Cancer mAbs market in Americas • Cancer mAbs market in EMEA • Cancer mAbs market in APAC PART 12: Market drivers • Increase in demand for ADCs • Special regulatory drug designations • Advanced technological innovations • Increase in industry-academia collaborations PART 13: Impact of drivers PART 14: Market challenges • Complicated regulatory framework • Absence of adequate diagnosis and screening procedures • High manufacturing costs coupled with stringent regulations • Threat from chemotherapy and off-label drugs PART 15: Impact of drivers and challenges PART 16: Market trends • Emergence of targeted and combination therapies • Joint ventures and partnerships for R&D • Advent of biosimilars expected to improve the treatment rates PART 17: Vendor landscape • Competitive scenario • Key news • Other prominent vendors PART 18: Key vendor analysis • Amgen • Bristol-Myers Squibb • F. Hoffmann-La Roche • Takeda Pharmaceuticals PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Offerings Exhibit 02: Key buying criteria for cancer mAbs 2016 Exhibit 03: Impact of key customer segments on the market 2016 Exhibit 04: Comparison of small molecule and mAbs Exhibit 05: Preparation of mAbs Exhibit 06: Types of mAbs Exhibit 07: Targeted mechanisms of cancer mAbs Exhibit 08: Timeline of mAbs for cancer Exhibit 09: Global cancer mAbs market: Share of pipeline molecules Exhibit 10: Global cancer mAbs market: Phase III pipeline molecules Exhibit 11: Global cancer mAbs market: Phase II pipeline molecules Exhibit 12: Global cancer mAbs market: Phase I pipeline molecules Exhibit 13: Overview of global cancer mAb market 2016-2021 Exhibit 14: Global cancer mAbs market snapshot: Developed and emerging markets 2016 Exhibit 15: Global cancer mAbs market 2016-2021 ($ billions) Exhibit 16: A few of patient assistance programs offered by various drugs Exhibit 17: Few awareness programs for various cancers Exhibit 18: Patent expiries of top-selling mAbs by 2021 in US Exhibit 19: Patent expiries of top selling mAbs by 2021 in Europe Exhibit 20: Annual treatment cost per patient for various oncology drugs 2015 Exhibit 21: Analysis of global cancer mAbs market by type of application Exhibit 22: Five forces analysis Exhibit 23: Market share of global cancer mAbs market by type of mAbs: Exhibit 24: US FDA- and EU-approved naked cancer mAbs Exhibit 25: Currently available conjugated mAbs Exhibit 26: Market segmentation by MOA Exhibit 27: Global cancer mAbs market revenue by geography 2016-2021 ($ billions) Exhibit 28: Overview of cancer mAbs market in Americas Exhibit 29: Cancer mAbs market in Americas 2016-2021 ($ billions) Exhibit 30: Cancer mAb market in Americas: Opportunity analysis Exhibit 31: Cancer mAbs market in Americas by country 2015 Exhibit 32: Cancer mAbs market in US 2016-2021 ($ billions) Exhibit 33: Overview of cancer mAbs market in EMEA Exhibit 34: Cancer mAbs market in EMEA 2016-2021 ($ billions) Exhibit 35: Cancer mAbs market in EMEA by country 2016 Exhibit 36: Cancer mAb market in EMEA: Opportunity analysis Exhibit 37: Overview of cancer mAbs market in APAC Exhibit 38: Cancer mAbs market in APAC 2016-2020 ($ billions) Exhibit 39: Cancer mAb market in APAC: Opportunity analysis Exhibit 40: Timeline of ADCs Exhibit 41: ADC molecules under clinical trials Exhibit 42: Special regulatory designations approved by US FDA Exhibit 43: Special regulatory designations approved by EU Exhibit 44: Advances in ADCs technology Exhibit 45: Advances in engineered and bispecific antibodies technology Exhibit 46: Impact of drivers Exhibit 47: Impact of drivers and challenges Exhibit 48: Expected combination regimen launches in oncology Exhibit 49: Market share analysis 2016 Exhibit 50: YoY sales comparison of top cancer mAbs 2013-2015 ($ billions) Exhibit 51: Competitive assessment of vendors Exhibit 52: Key vendors: Geographical presence 2015 Exhibit 53: Amgen: Key highlights Exhibit 54: Amgen: Strength assessment Exhibit 55: Amgen: Strategy assessment Exhibit 56: Amgen: Opportunity assessment Exhibit 57: Bristol-Myers Squibb: Key highlights Exhibit 58: Bristol-Myers Squibb: Strength assessment Exhibit 59: Bristol-Myers Squibb: Strategy assessment Exhibit 60: Bristol-Myers Squibb: Opportunity assessment Exhibit 61: Hoffmann-La Roche: Key highlights Exhibit 62: F. Hoffmann-La Roche: Strength assessment Exhibit 63: F. Hoffmann-La Roche: Strategy assessment Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment Exhibit 65: Takeda Pharmaceuticals: Highlights Exhibit 66: Takeda Pharmaceuticals: Strength assessment Exhibit 67: Takeda Pharmaceuticals: Strategy assessment Exhibit 68: Takeda Pharmaceuticals: Opportunity assessment

F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, Takeda Pharmaceuticals, AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.